Literature DB >> 23645664

Prevalence of and risk factors for chronic arthralgia and rheumatoid-like polyarthritis more than 2 years after infection with chikungunya virus.

Khadijah Essackjee1, Smita Goorah, Satish Kumar Ramchurn, Jayrani Cheeneebash, Karen Walker-Bone.   

Abstract

OBJECTIVES: Chikungunya virus (CHIKV), transmitted to humans from infected mosquitoes, causes acute fever, arthralgia and rash. There is increasing evidence that it also causes longer-term rheumatic symptoms. In a circumscribed part of Mauritius where infectivity was high, a cohort of inhabitants was surveyed with the objectives of assessing the prevalence of and risk factors for chronic musculoskeletal symptoms and for a rheumatoid arthritis-like condition at 27.5 months after initial infection.
METHODS: Participants were recruited May-November 2008 and invited to complete a questionnaire. CHIKV was diagnosed clinically. The primary outcomes for the analyses were (a) self-reported ongoing musculoskeletal symptoms and (b) fulfilment of modified diagnostic criteria for rheumatoid arthritis. Risk factors for these outcomes were explored in univariate analyses using logistic regression. Subsequently, multivariate logistic regression was used to identify factors that were independently associated with the outcomes.
RESULTS: 173 individuals were identified with CHIKV, of whom 136 (78.6%) reported persisting musculoskeletal symptoms 27.5 months after infection. Persistent symptoms were associated with older age at time of infection, female gender and baseline symmetrical distribution of joint symptoms. We found that 5% of those infected with CHIKV fulfilled a modified version of the American College of Rheumatology criteria for rheumatoid arthritis 27.5 months after infection.
CONCLUSIONS: CHIKV is associated with a high prevalence of persistent rheumatic symptoms. Physicians need to be aware of CHIKV as a cause of acute and chronic rheumatic symptoms.

Entities:  

Keywords:  EPIDEMIOLOGY; PUBLIC HEALTH; RHEUMATOLOGY

Mesh:

Year:  2013        PMID: 23645664     DOI: 10.1136/postgradmedj-2012-131477

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  25 in total

Review 1.  Management of chikungunya arthritis.

Authors:  J Kennedy Amaral Pereira; Robert T Schoen
Journal:  Clin Rheumatol       Date:  2017-08-03       Impact factor: 2.980

2.  Dynamics of Chikungunya Virus Cell Entry Unraveled by Single-Virus Tracking in Living Cells.

Authors:  Tabitha E Hoornweg; Mareike K S van Duijl-Richter; Nilda V Ayala Nuñez; Irina C Albulescu; Martijn J van Hemert; Jolanda M Smit
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

3.  Occurrence of Chronic Stage Chikungunya in the General Population of Martinique during the First 2014 Epidemic: A Prospective Epidemiological Study.

Authors:  Brieg Couzigou; Anne Criquet-Hayot; Emilie Javelle; Sandrine Tignac; Edith Mota; François Rigaud; Alizé Alain; Odile Troisgros; Sandrine Pierre-Francois; Sylvie Abel; Rishika Banydeen; André Cabié
Journal:  Am J Trop Med Hyg       Date:  2018-05-24       Impact factor: 2.345

Review 4.  Persistent RNA virus infections: do PAMPS drive chronic disease?

Authors:  Mary K McCarthy; Thomas E Morrison
Journal:  Curr Opin Virol       Date:  2017-02-17       Impact factor: 7.090

5.  Clinical Manifestations Associated with Peripheral Joint Involvement in Patients with Acute Chikungunya Virus Infection.

Authors:  Mariangelí Arroyo-Ávila; Amanda Cabán; Enid J García-Rivera; Marisela Irizarry-Pérez; Hilda Torres; Héctor Gorbea; Luis M Vilá
Journal:  Am J Trop Med Hyg       Date:  2017-01-30       Impact factor: 2.345

Review 6.  Chikungunya Infection: a Global Public Health Menace.

Authors:  A J Mathew; A Ganapati; J Kabeerdoss; A Nair; N Gupta; P Chebbi; S K Mandal; Debashish Danda
Journal:  Curr Allergy Asthma Rep       Date:  2017-02       Impact factor: 4.806

7.  γδ T Cells Play a Protective Role in Chikungunya Virus-Induced Disease.

Authors:  Kristin M Long; Martin T Ferris; Alan C Whitmore; Stephanie A Montgomery; Lance R Thurlow; Charles E McGee; Carlos A Rodriguez; Jean K Lim; Mark T Heise
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

8.  Prime-boost immunization strategies against Chikungunya virus.

Authors:  David Hallengärd; Fok-Moon Lum; Beate M Kümmerer; Aleksei Lulla; Valeria Lulla; Juan García-Arriaza; John K Fazakerley; Pierre Roques; Roger Le Grand; Andres Merits; Lisa F P Ng; Mariano Esteban; Peter Liljeström
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

9.  Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.

Authors:  David Hallengärd; Maria Kakoulidou; Aleksei Lulla; Beate M Kümmerer; Daniel X Johansson; Margit Mutso; Valeria Lulla; John K Fazakerley; Pierre Roques; Roger Le Grand; Andres Merits; Peter Liljeström
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

10.  Seroprevalence and Symptomatic Attack Rate of Chikungunya Virus Infection, United States Virgin Islands, 2014-2015.

Authors:  Morgan J Hennessey; Esther M Ellis; Mark J Delorey; Amanda J Panella; Olga I Kosoy; Hannah L Kirking; Grace D Appiah; Jin Qin; Alison J Basile; Leora R Feldstein; Brad J Biggerstaff; Robert S Lanciotti; Marc Fischer; J Erin Staples
Journal:  Am J Trop Med Hyg       Date:  2018-11       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.